Biological and Pharmaceutical Bulletin
Online ISSN : 1347-5215
Print ISSN : 0918-6158
ISSN-L : 0918-6158
A Novel Immunomodulator, FTY720, Prevents Development of Experimental Autoimmune Myasthenia Gravis in C57BL/6 Mice
Takeyuki KohnoTakumi TsujiKaori HirayamaRumi IwatsukiMichitaka HiroseKazuhito WatabeHiroaki YoshikawaTomoko KohnoAkiko MatsumotoTetsuro FujitaMasatoshi Hayashi
Author information

2005 Volume 28 Issue 4 Pages 736-739


Prophylactic oral administration of a novel immunomodulator (immunosuppressant), FTY720 (1 mg/kg, three times a week), completely prevented the development of experimental autoimmune myasthenia gravis (EAMG) in C57BL/6 mice. EAMG has been used as an animal model for human myasthenia gravis, and was established by immunizing the mice with acetylcholine receptor (AChR) from Torpedo californica. FTY720 also suppressed the production of both anti-Torpedo californica AChR antibody and anti-mouse AChR autoantibody by the mice, which were observed in mice in which EAMG had become established. These results strongly suggest that FTY720 is a promising candidate for treatment of human myasthenia gravis.

Information related to the author
© 2005 The Pharmaceutical Society of Japan
Previous article Next article